LATEST NEWS
GenVivo Latest News
GenVivo Highlights Non-Integrating Retroviral Vector Technology with Persistent Payload Expression at the 2025 Retroviruses Meeting
May 21, 2025
Read More >
GenVivo Highlights GEN2 Phase 1 Data and GEN-1013 Preclinical Data at the 2025 American Society of Gene + Cell Therapy (ASGCT) Annual Meeting
May 14, 2025
Read More >
GenVivo Highlights GEN-1013: A Novel Delivery of an IL-12 Immunotherapy at the 2025 American Association for Cancer Research (AACR) Annual Meeting
Apr 25, 2025
Read More >
GenVivo to Present Phase 1 Trial Results for GEN2, A Personalizing Gene Vector Therapy, at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting
Nov 8, 2024
Read More >
GenVivo Announces Initiation of Patient Dosing in a US Phase I/Ib Clinical Trial Evaluating GEN2, a Personalizing, Gene Vector Immunotherapy, in Patients with Advanced Solid Tumors
Jun 27, 2024
Read More >
GenVivo to Present Pipeline Programs at the 2024 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
May 8, 2024
Read More >
